Universe Pharmaceuticals (UPC) AI Stock Analysis

• Market Cap: $2.95M
• Dividend Yield: N/A
• Average Volume (3M): 955.25K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.68
• Revenue Growth: -27.81%
• EPS Growth: N/A
• Country: US
• Employees: 225
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 563,338
• 10 Day Avg. Volume: 2,486,504
• 30 Day Avg. Volume: 955,249
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -12.94
• Enterprise Value/Revenue: -1.98
• Enterprise Value/Gross Profit: -6.36
• Enterprise Value/Ebitda: -21.08
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: $5.50 ▲(6.18% Upside)

Universe Pharmaceuticals' stock score is primarily impacted by its financial difficulties, including declining revenues and profitability issues. Technical analysis shows some short-term strength, but the valuation is weak due to a lack of earnings and dividend yield. These factors collectively result in a below-average stock score.

Universe Pharmaceuticals Business Overview & Revenue Model

Company Description

Universe Pharmaceuticals (UPC) is a biotechnology company focused on the research, development, and commercialization of innovative pharmaceutical products. Operating primarily in the healthcare sector, UPC specializes in creating advanced therapeutics that address unmet medical needs, particularly in areas such as oncology, neurology, and infectious diseases. The company's core offerings include a pipeline of novel drug candidates, as well as partnerships for the development of generics and biosimilars.

How the Company Makes Money

Universe Pharmaceuticals generates revenue through multiple streams. The primary revenue model is based on the sale of pharmaceutical products, including both proprietary medications and partnerships in generic drug development. Additionally, UPC earns income through licensing agreements, where it collaborates with other pharmaceutical companies to co-develop drugs or grant rights for distribution. The company may also receive milestone payments and royalties based on the performance of its products in the market. Strategic partnerships with research institutions and industry players further enhance UPC's revenue potential by providing access to additional resources and expertise in drug development.

Universe Pharmaceuticals Financial Statement Overview

Summary

Universe Pharmaceuticals faces financial difficulties characterized by declining revenues, persistent losses, and cash flow challenges. The balance sheet is moderately leveraged but stable, indicating some asset stability amidst financial strain.

Income Statement

Universe Pharmaceuticals has experienced declining revenue over recent years, with a significant drop from 2020 to 2024. The company has shifted from profitability to consistent losses, highlighted by negative net income margins in recent periods. Gross profit margins have contracted, and EBIT and EBITDA margins have turned negative, indicating operational challenges.

Balance Sheet

The balance sheet shows a moderate level of leverage with a debt-to-equity ratio that remains manageable. However, equity has decreased over the years, reflecting financial strain. Despite this, the company maintains a solid equity ratio, suggesting some level of asset stability.

Cash Flow

Universe Pharmaceuticals faces challenges in cash flow generation, with negative operating cash flow observed in the latest period. Free cash flow has been volatile, turning negative in recent years, and the free cash flow to net income ratio reflects operational inefficiencies. Despite these issues, financing activities have provided liquidity support.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	23.02M	32.31M	40.14M	47.98M	30.70M
Gross Profit	6.07M	10.32M	21.89M	25.33M	14.09M
EBITDA	-7.36M	-3.22M	-6.40M	14.20M	10.61M
Net Income	-8.73M	-6.16M	-8.74M	11.32M	7.56M
Balance Sheet
Total Assets	67.95M	53.29M	59.54M	70.14M	28.80M
Cash, Cash Equivalents and Short-Term Investments	29.50M	18.50M	18.86M	21.80M	10.06M
Total Debt	7.99M	5.48M	3.94M	4.33M	2.65M
Total Liabilities	22.45M	13.75M	13.10M	11.21M	8.00M
Stockholders Equity	45.50M	39.53M	46.44M	58.93M	20.80M
Cash Flow
Free Cash Flow	-9.87M	1.08M	-1.41M	-15.59M	6.06M
Operating Cash Flow	-9.51M	1.12M	-1.31M	-2.06M	6.12M
Investing Cash Flow	-361.29K	-44.17K	-3.91M	-27.06M	-51.80K
Financing Cash Flow	33.95M	-1.39M	3.32M	26.58M	470.14K

Universe Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UPC, the sentiment is Neutral. The current price of 5.18 is below the 20-day moving average (MA) of 5.46, above the 50-day MA of 4.48, and below the 200-day MA of 5.96, indicating a neutral trend. The MACD of 0.21 indicates Positive momentum. The RSI at 50.16 is Neutral, neither overbought nor oversold. The STOCH value of 18.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for UPC.

Universe Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COSM	54 Neutral	$32.25M	―	-52.69%	―	―	―
UPC	52 Neutral	$2.95M	―	2.66%	―	-27.81%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
YCBD	44 Neutral	$8.91M	-0.17	-33.13%	―	-7.80%	90.17%
CPHI	43 Neutral	$5.48M	-1.13	-52.05%	―	-29.64%	73.63%

Universe Pharmaceuticals Corporate Events

Universe Pharmaceuticals Approves Key Resolutions at 2025 AGM

On September 2, 2025, Universe Pharmaceuticals INC held its reconvened annual general meeting of shareholders after an initial meeting on August 26, 2025, was adjourned due to a lack of quorum. During the meeting, shareholders approved all proposals, including the re-election of directors and a significant capital reduction plan. The capital reduction involves reducing the par value of shares and altering the company’s share capital structure, which is expected to provide greater financial flexibility and potentially improve shareholder value.

Universe Pharmaceuticals Postpones Annual General Meeting Due to Quorum Issue

On August 26, 2025, Universe Pharmaceuticals INC had to adjourn its 2025 annual general meeting due to a lack of quorum. The meeting has been rescheduled to September 2, 2025, at the same location in Ji’an City, China. This adjournment may impact the company’s operational timelines and decision-making processes, potentially affecting stakeholders awaiting outcomes from the meeting.

Universe Pharmaceuticals Announces 2025 AGM and Major Capital Reorganization

On July 29, 2025, Universe Pharmaceuticals INC announced its 2025 Annual General Meeting of Shareholders, scheduled for August 26, 2025, in Jiangxi, China. Key agenda items include the re-election of directors and a significant capital reorganization involving a reduction in the par value of shares, the creation of new share classes, and the adoption of amended articles of association. This restructuring aims to streamline the company’s capital structure and potentially enhance shareholder value.